292 related articles for article (PubMed ID: 33989680)
1. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
Tuesuwan B; Vongsutilers V
J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
3. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
4. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
5. Nitrosamine Impurities in Herbal Formulations: A Review of Risks and Mitigation Strategies.
Shekhar NR; Nagappan K; Singh MT; Dhanabal SP
Drug Res (Stuttg); 2023 Oct; 73(8):431-440. PubMed ID: 37487523
[TBL] [Abstract][Full Text] [Related]
6. NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.
Tchernev G; Kordeva S
Georgian Med News; 2023 Apr; (337):63-67. PubMed ID: 37354675
[TBL] [Abstract][Full Text] [Related]
7. Current Threat of Nitrosamines in Pharmaceuticals and Scientific Strategies for Risk Mitigation.
Tuesuwan B; Vongsutilers V
J Pharm Sci; 2023 May; 112(5):1192-1209. PubMed ID: 36739905
[TBL] [Abstract][Full Text] [Related]
8. A GC-MS/MS Method for Trace Level Quantification of Six Nitrosamine Impurities (NDMA, NDEA, NEIPA, NDIPA, NDPA, and NDBA) in Commercially Used Organic Solvents: Dichloromethane, Ethyl Acetate, Toluene, and O-xylene.
Kosuri ER; Bhanti M; Jaywant MA; Han M; Wang X; Obeng M
J Pharm Sci; 2023 May; 112(5):1225-1230. PubMed ID: 36462706
[TBL] [Abstract][Full Text] [Related]
9. Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography Tripple Quadrupole Mass Spectrometry.
Solanki R; Wadhwana P; Patel R; Gayakvad B; Kothari C; Patel C
J Pharm Sci; 2023 May; 112(5):1268-1276. PubMed ID: 36822274
[TBL] [Abstract][Full Text] [Related]
10. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
11. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.
Scherf-Clavel O; Kinzig M; Besa A; Schreiber A; Bidmon C; Abdel-Tawab M; Wohlfart J; Sörgel F; Holzgrabe U
J Pharm Biomed Anal; 2019 Aug; 172():278-284. PubMed ID: 31078064
[TBL] [Abstract][Full Text] [Related]
12. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques.
Shaik KM; Sarmah B; Wadekar GS; Kumar P
Crit Rev Anal Chem; 2022; 52(1):53-71. PubMed ID: 32691615
[TBL] [Abstract][Full Text] [Related]
13. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
14. In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products.
Tsuji G; Kurohara T; Shoda T; Yokoo H; Ito T; Masada S; Uchiyama N; Yamamoto E; Demizu Y
Chem Pharm Bull (Tokyo); 2024; 72(2):166-172. PubMed ID: 38296559
[TBL] [Abstract][Full Text] [Related]
15. Presence of nitrosamine impurities in medicinal products.
Sedlo I; Kolonić T; Tomić S
Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
[TBL] [Abstract][Full Text] [Related]
16. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
[TBL] [Abstract][Full Text] [Related]
17. NITROSOGENESIS OF SKIN CANCER: THE NITROSAMINE CONTAMINATION IN THE CALCIUM CHANNEL BLOCKERS (AMLODIPINE), BETA BLOCKERS (BISOPROLOL), SARTANS (VALSARTAN/LOSARTAN), ACE INHIBITORS (PERINDOPRIL/ENALAPRIL), TRICYCLIC ANTIDEPRESSANTS (MELITRACEN), SSRIS (PAROXETINE), SNRIS (VENLAFAXINE) AND METFORMIN: THE MOST PROBABLE EXPLANATION FOR THE RISING SKIN CANCER INCIDENCE.
Tchernev G
Georgian Med News; 2023 Jun; (339):24-32. PubMed ID: 37522769
[TBL] [Abstract][Full Text] [Related]
18. Analytical lifecycle management for comprehensive and universal nitrosamine analysis in various pharmaceutical formulations by supercritical fluid chromatography.
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
J Pharm Biomed Anal; 2021 Apr; 197():113960. PubMed ID: 33626447
[TBL] [Abstract][Full Text] [Related]
19. NITROSAMINE CONTAMINATION WITHIN CARDIAC MULTIMEDICATION - SARTANS (VALSARTAN), CALCIUM CHANNEL BLOCKERS (AMLODIPINE AND NIFEDIPINE), AND ANTIARRHYTHMICS (PROPAFENONE) AS A SIGNIFICANT FACTOR IN THE DEVELOPMENT AND PROGRESSION OF MULTIPLE KERATINOCYTIC CANCERS: ADVANCEMENT ROTATION FLAP FOR KERATOACANTHOMA OF THE UPPER LIP AND UNDERMINING SURGERY FOR BCC OF THE SHOULDER AS AN OPTIMAL DERMATOSURGICAL APPROACH.
Tchernev G
Georgian Med News; 2023 Sep; (342):152-155. PubMed ID: 37991972
[TBL] [Abstract][Full Text] [Related]
20. The EU Response to the Presence of Nitrosamine Impurities in Medicines.
Ruepp R; Frötschl R; Bream R; Filancia M; Girard T; Spinei A; Weise M; Whomsley R
Front Med (Lausanne); 2021; 8():782536. PubMed ID: 34869504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
